BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38151733)

  • 1. Sublingual immunotherapy tablets in monosensitized and polysensitized adults with allergic rhinoconjunctivitis.
    Nelson HS; Bernstein DI; Biedermann T; Nolte H
    Allergy Asthma Proc; 2024 Jan; 45(1):33-36. PubMed ID: 38151733
    [No Abstract]   [Full Text] [Related]  

  • 2. Sublingual Tablet Immunotherapy Improves Quality of Life in Adults With Allergic Rhinoconjunctivitis.
    Blaiss MS; Durham SR; Bernstein D; Stranzl T; Lindholm M; Nolte H; Andersen KF; Roberts G
    J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1520-1529.e5. PubMed ID: 38307205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Ragweed SLIT-Tablet in Children with Allergic Rhinoconjunctivitis in a Randomized, Placebo-Controlled Trial.
    Nolte H; Bernstein DI; Nelson HS; Ellis AK; Kleine-Tebbe J; Lu S
    J Allergy Clin Immunol Pract; 2020; 8(7):2322-2331.e5. PubMed ID: 32304832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
    Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
    Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of house dust mite sublingual immunotherapy tablet in North American adolescents and adults in a randomized, placebo-controlled trial.
    Nolte H; Bernstein DI; Nelson HS; Kleine-Tebbe J; Sussman GL; Seitzberg D; Rehm D; Kaur A; Li Z; Lu S
    J Allergy Clin Immunol; 2016 Dec; 138(6):1631-1638. PubMed ID: 27521719
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of the SQ house dust mite sublingual immunotherapy tablet in Japanese adults and adolescents with house dust mite-induced allergic rhinitis.
    Okubo K; Masuyama K; Imai T; Okamiya K; Stage BS; Seitzberg D; Konno A
    J Allergy Clin Immunol; 2017 Jun; 139(6):1840-1848.e10. PubMed ID: 27864024
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of house dust mite sublingual immunotherapy in monosensitized and polysensitized children with respiratory allergic diseases.
    Li P; Li Q; Huang Z; Chen W; Lu Y; Tian M
    Int Forum Allergy Rhinol; 2014 Oct; 4(10):796-801. PubMed ID: 25145986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment effect of sublingual immunotherapy tablets and pharmacotherapies for seasonal and perennial allergic rhinitis: Pooled analyses.
    Durham SR; Creticos PS; Nelson HS; Li Z; Kaur A; Meltzer EO; Nolte H
    J Allergy Clin Immunol; 2016 Oct; 138(4):1081-1088.e4. PubMed ID: 27527264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epinephrine Use in Clinical Trials of Sublingual Immunotherapy Tablets.
    Nolte H; Casale TB; Lockey RF; Fogh BS; Kaur A; Lu S; Nelson HS
    J Allergy Clin Immunol Pract; 2017; 5(1):84-89.e3. PubMed ID: 27838323
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-Term Efficacy of Sublingual Mite Immunotherapy in Monosensitized and Polysensitized Children with Allergic Rhinitis: A 7-Year Prospective Study.
    Cui L; Li J; Li Y; Xia Z
    Int Arch Allergy Immunol; 2019; 180(2):144-149. PubMed ID: 31256165
    [TBL] [Abstract][Full Text] [Related]  

  • 11. House dust mite allergen immunotherapy for monosensitized versus polysensitized patients with allergic rhinitis: A systematic review and meta-analysis.
    Phinyo P; Krikeerati T; Wongyikul P; Lao-Araya M; Thongngarm T
    Asian Pac J Allergy Immunol; 2022 Dec; 40(4):337-352. PubMed ID: 36278778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of sublingual allergen immunotherapy.
    DuBuske L
    Allergy Asthma Proc; 2022 Jul; 43(4):272-280. PubMed ID: 35818141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
    Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
    J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
    Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
    Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy With the SQ Tree SLIT-tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis.
    Mäkelä MJ; Gyllfors P; Valovirta E; Steffensen MA; Grønager PM; Savolainen J; Winther L
    Clin Ther; 2018 Apr; 40(4):574-586.e4. PubMed ID: 29551533
    [TBL] [Abstract][Full Text] [Related]  

  • 16. House dust mite sublingual immunotherapy tablet safety in adolescents with allergic rhinoconjunctivitis: Worldwide clinical trial results.
    Horn A; Bernstein DI; Okubo K; Dalgaard T; Hels O; Sørensen HF; Henriksen M; Azuma R; Mikler J; Nolte H
    Ann Allergy Asthma Immunol; 2023 Jun; 130(6):797-804.e2. PubMed ID: 36924936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SQ house dust mite sublingual immunotherapy tablet subgroup efficacy and local application site reaction duration.
    Bernstein DI; Kleine-Tebbe J; Nelson HS; Bardelas JA; Sussman GL; Lu S; Rehm D; Svanholm Fogh B; Nolte H
    Ann Allergy Asthma Immunol; 2018 Jul; 121(1):105-110. PubMed ID: 29656145
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of ragweed sublingual immunotherapy in Canadian patients with allergic rhinoconjunctivitis.
    Kim H; Waserman S; Hébert J; Blaiss M; Nelson H; Creticos P; Kaur A; Maloney J; Li Z; Nolte H
    Allergy Asthma Clin Immunol; 2014; 10(1):55. PubMed ID: 25788949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of SQ house dust mite sublingual immunotherapy-tablet in Japanese children.
    Masuyama K; Okamoto Y; Okamiya K; Azuma R; Fujinami T; Riis B; Ohashi-Doi K; Natsui K; Imai T; Okubo K
    Allergy; 2018 Dec; 73(12):2352-2363. PubMed ID: 30043449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized controlled trial of ragweed sublingual immunotherapy tablet in the subpopulation of Canadian children and adolescents with allergic rhinoconjunctivitis.
    Ellis AK; Gagnon R; Bernstein DI; Nolte H
    Allergy Asthma Clin Immunol; 2021 Dec; 17(1):127. PubMed ID: 34886880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.